Search Results

There are 8583 results for: content related to: Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

  1. You have free access to this content
    Ropinirole, a Non-Ergoline Dopamine Agonist

    CNS Drug Reviews

    Volume 11, Issue 3, September 2005, Pages: 253–272, Wolfgang H. Jost and Dieter Angersbach

    Version of Record online : 7 JUN 2006, DOI: 10.1111/j.1527-3458.2005.tb00046.x

  2. Dopamine agonists for the treatment of restless legs syndrome

    Intervention Review

    The Cochrane Library

    Hanna Scholz, Claudia Trenkwalder, Ralf Kohnen, Levente Kriston, Dieter Riemann and Magdolna Hornyak

    Published Online : 15 MAR 2011, DOI: 10.1002/14651858.CD006009.pub2

  3. PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease

    Movement Disorders

    Volume 26, Issue 7, June 2011, Pages: 1259–1265, Fabrizio Stocchi, Luigi Giorgi, Brian Hunter and Anthony HV Schapira

    Version of Record online : 5 APR 2011, DOI: 10.1002/mds.23498

  4. Pharmacokinetics and effect of food after oral administration of prolonged-release tablets of ropinirole hydrochloride in Japanese patients with Parkinson’s disease

    Journal of Clinical Pharmacy and Therapeutics

    Volume 37, Issue 5, October 2012, Pages: 571–577, N. Hattori, K. Hasegawa and T. Sakamoto

    Version of Record online : 6 MAR 2012, DOI: 10.1111/j.1365-2710.2012.01336.x

  5. You have free access to this content
    Comparison of ropinirole controlled- and immediate-release in Japanese patients with advanced Parkinson's disease

    Neurology and Clinical Neuroscience

    Volume 3, Issue 1, January 2015, Pages: 18–24, Nobutaka Hattori, Hiroshi Nishioka, Kazuko Hasegawa and on behalf of the SWAN Study Investigators

    Version of Record online : 25 NOV 2014, DOI: 10.1111/ncn3.128

  6. DA agonists - Non-Ergot derivaties: Ropinirole

    Movement Disorders

    Volume 17, Issue S4, July/August 2002, Pages: S98–S102,

    Version of Record online : 29 JUL 2002, DOI: 10.1002/mds.5570

  7. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease

    Movement Disorders

    Volume 24, Issue 14, 30 October 2009, Pages: 2121–2127, Kelly E. Lyons and Rajesh Pahwa

    Version of Record online : 18 SEP 2009, DOI: 10.1002/mds.22750

  8. Ropinirole for levodopa-induced complications in Parkinson's disease

    Intervention Review

    The Cochrane Library

    Carl E Clarke and Katherine HO Deane

    Published Online : 22 JAN 2001, DOI: 10.1002/14651858.CD001516

  9. You have free access to this content
    D2/D3 receptor agonist ropinirole protects dopaminergic cell line against rotenone-induced apoptosis through inhibition of caspase- and JNK-dependent pathways

    FEBS Letters

    Volume 582, Issue 5, March 05, 2008, Pages: 603–610, Sheng Chen, Xiaojie Zhang, Dehua Yang, Yunlan Du, Liang Li, Xuping Li, Ming Ming and Weidong Le

    Version of Record online : 31 JAN 2008, DOI: 10.1016/j.febslet.2008.01.028

  10. Lack of a Pharmacokinetic Interaction at Steady State Between Ropinirole and L-Dopa in Patients with Parkinson's Disease

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 19, Issue 2, February 1999, Pages: 150–156, Dr. Anne C. Taylor, Dr. Almisbah Beerahee, Dr. David R. Citerone, Dr. Matthew J. Cyronak, Dr. Terry J. Leigh, Dr. Katherine L. Fitzpatrick, Dr. Arturo Lopez-Gil, Dr. Sarosh D. Vakil, Dr. Eileen Burns and Dr. Graham Lennox

    Version of Record online : 17 JAN 2012, DOI: 10.1592/phco.19.3.150.30927

  11. Abstracts of The Movement Disorder Society's Twelfth International Congress of Parkinson's Disease and Movement Disorders

    Movement Disorders

    Volume 23, Issue S1, 15 May 2008, Pages: S1–S422,

    Version of Record online : 28 MAY 2008, DOI: 10.1002/mds.22133

  12. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study

    Movement Disorders

    Volume 13, Issue 1, January 1998, Pages: 46–51, Prof. Amos D. Korczyn, David J. Brooks, Ehrout R. Brunt, Warner H. Poewe, Olivier Rascol and Fabrizzio Stocchi

    Version of Record online : 4 NOV 2004, DOI: 10.1002/mds.870130112

  13. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

    Movement Disorders

    Volume 26, Issue S3, October 2011, Pages: S2–S41, Susan H. Fox, Regina Katzenschlager, Shen-Yang Lim, Bernard Ravina, Klaus Seppi, Miguel Coelho, Werner Poewe, Olivier Rascol, Christopher G. Goetz and Cristina Sampaio

    Version of Record online : 21 OCT 2011, DOI: 10.1002/mds.23829

  14. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa

    Movement Disorders

    Volume 21, Issue 11, November 2006, Pages: 1844–1850, Olivier Rascol, David J. Brooks, Amos D. Korczyn, Peter P. De Deyn, Carl E. Clarke, Anthony E. Lang and Mona Abdalla

    Version of Record online : 6 SEP 2006, DOI: 10.1002/mds.20988

  15. Preparation and biological evaluation of 99mTc–ropinirole as a novel radiopharmaceutical for brain imaging

    Journal of Labelled Compounds and Radiopharmaceuticals

    Volume 59, Issue 4, April 2016, Pages: 147–152, M. A. Motaleb, I. T. Ibrahem, V. R. Ayoub and A. S. Geneidi

    Version of Record online : 23 FEB 2016, DOI: 10.1002/jlcr.3380

  16. You have free access to this content
    Interactions between domperidone and ropinirole, a novel dopamine D2- receptor agonist.

    British Journal of Clinical Pharmacology

    Volume 32, Issue 4, October 1991, Pages: 483–488, C de Mey, D Enterling, I Meineke and S Yeulet

    Version of Record online : 26 JUL 2012, DOI: 10.1111/j.1365-2125.1991.tb03935.x

  17. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease

    Intervention Review

    The Cochrane Library

    Carl E Clarke and Katherine HO Deane

    Published Online : 22 JAN 2001, DOI: 10.1002/14651858.CD001517

  18. A single and multiple dose study to investigate the pharmacokinetics of a prolonged release formulation of ropinirole in healthy Chinese subjects

    Clinical Pharmacology in Drug Development

    Volume 3, Issue 2, March/April 2014, Pages: 84–92, Hongzhong Liu, Ji Jiang, Hongyun Wang, Xia Chen, Tao Liu, Haijun Cao, Jonathan Palmer, Anita Gu and Pei Hu

    Version of Record online : 30 OCT 2013, DOI: 10.1002/cpdd.28

  19. Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom Disease): Results from a prospective, multicenter study over 66 weeks

    Movement Disorders

    Volume 27, Issue 2, February 2012, Pages: 277–283, Diego García-Borreguero, Birgit Högl, Luigi Ferini-Strambi, John Winkelman, Christina Hill-Zabala, Afsaneh Asgharian and Richard Allen

    Version of Record online : 4 JAN 2012, DOI: 10.1002/mds.24889

  20. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus)

    Movement Disorders

    Volume 16, Issue 4, July 2001, Pages: 631–641, Eleni C. Maratos, Michael J. Jackson, Ronald K. B. Pearce and Peter Jenner

    Version of Record online : 11 JUL 2001, DOI: 10.1002/mds.1149